Two bacteria passing the word: an internal clock to stabilise a living medicine

Excellent integration of an in silico modelling phase (Phase 1) with explicit GO/NO-GO/PIVOT criteria, enabling the identification of viable parametric regimes before any major experimental investment, thereby reducing the risk of resource waste.

The hypothesis proposes an elegant and theoretically grounded application of quorum sensing (QS) negative-feedback principles to stabilise a synthetic consortium, a central problem in distributed synthetic biology. The mechanism of inter-strain coupling via a toxin-antitoxin module (or equivalent) to create a growth-regulation loop is conceptually consistent with work on 'social reward-punishment' (DOI:10.1016/j.ymben.2019.03.009) and QS-based synchronisation (DOI:10.1371/journal.pcbi.1004881).

The modular approach and the quorum-sensing coupling to stabilise a synthetic consortium in the gut are conceptually elegant and draw on system-engineering principles verified in vitro.

A clear and immediate addressable market is identified: metabolic disorders (phenylketonuria, 1:10,000 births) and chronic inflammatory bowel diseases (IBD, approximately 5 million patients in the US/EU) represent an unmet need not addressed by conventional probiotics, with a high pricing potential (living therapy, >€50k/year/patient versus the current oral recombinant enzyme).

A highly mechanistic and falsifiable hypothesis is presented, with precise quantitative success criteria (CV < 0.15, production rate 0.5–2.0 mmol/g/h), a feature that is rare and highly valued by ERC/ANR project reviewers.